MedTrace Logo

Intercostobrachial Nerve Block (ICBN) for Tourniquet Pain: Is it Necessary?

NCT03797924 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2022-05-24

No results posted yet for this study

Summary

In this study the investigators would like to show that when patients undergo upper limb surgery under supraclavicular brachial plexus block, additional blocking of the Intercostobrachial Nerve Block (ICBN) does not affect the incidence or course of tourniquet pain.

Conditions

Interventions

DRUG

Receive ICBN with ropivacaine

ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.

BEHAVIORAL

No ICBN block

The site of injection will be prepped with tinted chlorhexidine

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Linda Le-Wendling, MD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-25
Primary Completion
2020-12-20
Completion
2021-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03797924 on ClinicalTrials.gov